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Glucagon-like peptide-2 (GLP-2) is a therapeutic target used in the treatment of short bowel syn-
drome. In this paper, we present the three dimensional solution structure of GLP-2 peptide deter-
mined using nuclear magnetic resonance (NMR) and molecular modelling. The GLP-2 adopts an
a-helical conformation similar to that of secretin family of hormones. In order to understand the
molecular details governing the ligand binding and receptor activation, macromolecular docking
studies were performed between the N-terminal extracellular domain of GLP-2 receptor and the
GLP-2 hormone using a data driven docking program.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Glucagon-like peptide-2 (GLP-2) is a 33 amino acid proglucagon
derived peptide, (HADGSFSDEM NTILDNLAAR DFINWLIQTK ITD),
secreted from enteroendocrine L cells after meal ingestion [1,2].
GLP-2 acts as an intestinal growth promoting agent in the small
and large bowel by promoting the expansion of epithelial mucosa
via stimulation of crypt cell proliferation and inhibition of apopto-
sis in the gut epithelium [3]. Studies in humans have shown an
apparent effect of intravenous GLP-2 on pancreatic endocrine
secretion, as revealed by increasing plasma glucagon levels thus
introducing a new role for GLP-2 in endocrine regulation [4,5].
The GLP-2 exerts its action by interacting with the heterotrimeric
G-protein coupled receptor belongs to glucagon/secretin super
family (Fig. 1). The GLP-2 activates intracellular signalling via
cAMP-dependent pathway in transfected ﬁbroblasts [6]. Literature
reports on various animal models of intestinal insufﬁciency havechemical Societies. Published by E
cose-dependent insulinotrop-
-2, glucagon-like peptide-2;
ine; NOESY, nuclear Overha-
esonance; RMSD, root mean
rrelation spectroscopy
ewage).shown the therapeutic potential of this intestinotropic hormone,
including short bowel, intestinal atrophy, enteritis and colitis
[7,8]. However, GLP-2 undergoes degradation through an enzyme,
dipeptidyl peptidase 4, at position 2 resulting in the truncated frag-
ment with short duration of action [9].
Current information available on GLP-2 action is mostly corre-
lated with pharmacological evaluations of GLP-2 and circular
dichroism spectroscopic studies [10]. Despite the emerging biolog-
ical importance of GLP-2, very little structural information is avail-
able on GLP-2 and or its receptor. Therefore, for the ﬁrst time, we
present the three dimensional solution structure of GLP-2 and its
receptor interaction studies as determined by nuclear magnetic
resonance (NMR) spectroscopy and advanced computational mod-
elling. The results of this study indicate that the GLP-2 adopts a sta-
ble a-helical conformation in the central region, a less well deﬁned
loose helical conformation at the C-terminal region. Using NMR-
derived solution conformations of GLP-2, we have identiﬁed the
important macromolecular docking interactions between the
GLP-2 hormone and its N-terminal extracellular receptor domain
(Nt-ECD). The receptor–hormone complex provides detailed
molecular insights of the GLP-2 hormone binding with its Nt-
ECD. The results presented here provide a valuable insight into
the structural and functional properties of GLP-2 and its receptor
interactions, which could help in the design of novel therapeutic
drugs that may be active at the GLP-2 receptor.lsevier B.V. All rights reserved.
Fig. 1. Multiple alignment of Nt-ECD of human GLP-2R amino acid sequences with the Nt-ECD of human GIP, glucagon, secretin and GLP-1 receptor sequences. Alignment
was performed with CLUSTAL-W 2.0.12. The signal peptide cleavage site for GLP-2R in the Nt-ECD is indicated by a triangle.
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2.1. NMR sample preparation
The GLP-2 peptide was supplied form by EZ-Biolab, U.S.A. The
peptide was further puriﬁed to near homogeneity by RP HPLC
and their structural identity was conﬁrmed by ES mass spectrom-
etry. NMR samples were prepared by dissolving the 4.5 mg of GLP-
2 peptide (2 mM) in 10%, 20% and 33% triﬂuroethanol (TFE)-d3:H2O
mixed solvent system. For studies in micellular environment the
sample was prepared by mixing 4.6 mg of GLP-2 peptide sample
in 540 ml 350 mM 1,2-dihexanoyl-sn-glycero-3-phosphatidylcho-
line (DHPC)-d22:H2O so that the sample contained a peptide to li-
pid ratio of 1:175 and D2O (60 ll) was added for spectrometer
locking.
2.2. NMR spectroscopy
NMR experiments were performed on Bruker Avance 500 NMR
spectrometer equipped with 5 mm inverse probe head at proton
resonance frequency of 500.13 MHz operating at 310 K. 2D total
correlation spectroscopy (TOCSY) (30 and 80 ms) [11], and nuclear
Overhauser effect spectroscopy (NOESY) (200 ms) [12] spectra
were acquired with a relaxation delay of 1.4 s, an acquisition time
of 0.40 s, and a spectral width of 12 kHz. TOCSY and NOESY exper-
iments were performed with 16 and 32 transients for each of 2048
t1 increments into 8192 complex data points, respectively. The
data were zero-ﬁlled to 4096 data points in F1, and apodized using
a shifted squared sinebell window function in both dimensions and
processed using the Bruker TOPSPIN software (version 2.1).
2.3. Structure calculations
NOESY spectra were analyzed with the SPARKY software (ver-
sion 3.110) [13]. The integrals of the NOEs were converted into dis-
tance constraints with CALIBA [14]. Pseudo atoms were also
introduced for protons which could not be stereo speciﬁcally as-
signed [15] and the structure calculations were carried out using
the CYANA (version 2.0) [16]. Two hundred random structures
were generated and their energy minimized using the anneal pro-
tocol in CYANA, that include 10 000 steps of simulated annealing
and 5000 steps of conjugate-gradient minimization. During the
CYANA calculations, distance constraints were weighted using
the force constant kNOE = 1 kJ mol1 Å2. The 20 structures withthe lowest target function values were subjected to 5000 steps of
unconstrained Powell minimization with SYBYL (version 10) using
the Tripos force ﬁeld [17]. MOLMOL [18] and PROCHECK-NMR [19]
were used for further structural analysis.
2.4. Docking of GLP-2 with extracellular domain
The structural model of Nt-ECD of human GLP-2 receptor was
predicted by using the protein homology recognition engine Phyre
<www.sbg.bio.ac.uk/phyre> [20]. Among the numerous templates
found with precision higher than 95%, the model based on the
extracellular domain of the glucagon-like peptide-1 (GLP-1) recep-
tor (PDB 3C59) was chosen as it displayed the highest sequence
similarity with Nt-ECD. Using this predicted structure, molecular
docking calculations were then performed with the solution con-
formation of GLP-2 hormone using a data driven docking program,
HADDOCK web server <http://haddock.chem.uu.nl/> [21]. HAD-
DOCK uses a high performance docking approach with a three step
protocol for performing the docking calculations. 1000 structures
were generated during rigid body docking stage, of which the best
200 structures based on their intermolecular energy were submit-
ted to the second stage of semi ﬂexible reﬁnement. All 200 struc-
tures were then reﬁned in the third stage using an explicit
solvent (in water) and were clustered based on the root mean
square deviation (RMSD). The lowest energy complex structure
was taken as the best model which was further analyzed by using
the YASARA software <http://www.yasara.org>.3. Results
3.1. Structure of GLP-2 hormone in TFE and DHPC media
Identiﬁcation of individual spin systems was achieved by direct
comparison of the TOCSY and NOESY spectra. For GLP-2 in TFE–
water medium, the residues between Ala2 and Thr32 were clearly
identiﬁed using aiH/Ni + 1H and NiH/Ni + 1H connectivities. The aiH/
Ni + 3H and aiH/bi + 3H connectivities indicated the occurrence of an
a-helical structure between the residues Phe6–Ile27. The medium
range aiH/Ni+4H connectivities were also found between the resi-
dues Ala2/Phe6, Asp15/Ala19, Ala18/Phe22, Arg20/Asn24, Asp21/
Trp25, Phe22/Leu26, Ile23/Ile27 and Gln28/Thr32. All these prom-
inent connectivity patterns conﬁrm the a-helical character of GLP-
2 in TFE–water mixed solvent medium.
Fig. 2. Short and medium range connectivities for GLP-2 in (a) TFE–water mixed solvent system and (b) in DHPC micellular media.
Fig. 3. Best ﬁt superposition of 10 structures for GLP-2 (a) in TFE–water mixed solvent system and (b) in DHPC micellular media.
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and NiH/Ni+1H connectivities supported the resonance assign-ments. The strong medium range aiH/Ni+3H connectivities ob-
served in the ﬁngerprint region between the residues Phe6 and
Fig. 4. Homology model of the Nt-ECD showing the secondary structure formations, helix in blue, strands in red, disulphide bridges and conserved residues. The model
presented is generated using the YASARA software <http://www.yasara.org>.
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Ni+4H medium range connectivities were also found between the
residues Thr12/Asn16, Asp15/Ala19, Arg20/Asn24, Asp21/Trp25,
Phe22/Leu26 and Gln28/Thr32. The complete set of NiH/Ni+1H,
aiH/Ni+3H, aiH/Ni+4H and aiH/bi+3H connectivity patterns conﬁrm
the a-helical character of GLP-2 in micellular medium (Fig. 2).
The structure calculation studies showed the occurrence of clear
alpha helical conformation for the GLP-2 hormone between resi-
dues Phe6–Ile27 and Phe6–Asp24 and an extended loose helical
turn for TFE–water and DHPC media, respectively. The calculated
solution structure showed a well deﬁned right handed alpha heli-
cal conformation (Fig. 3) as determined by MOLMOL and PRO-
CHECK-NMR.
3.2. Model of Nt-ECD
The core features of the homology model of Nt-ECD comprised
an unstructured N-terminal, an a-helix, b-strands (B1–B6) in the
central region, three disulphide bridges and the conserved residues
Asp101, Trp106, Pro119, Arg135, Gly141 and Trp143 in the central
region as shown in the Fig. 4. The single a-helix is deﬁned by 21
amino acid residues between Leu68 and Leu88. The disulphide
bridge between Cys96 and Cys137 connects the loop (L1) and the
end of B4 b-strand. Cys118 is positioned at the end of B3 b-strand
that forms the disulphide bridge with Cys159 at the C-terminal re-
gion of the extracellular domain (ECD). The two very short b-
strands between the residues Thr99–Phe100 (B1) and the residues
Val104–Trp106 (B2) form the ﬁrst antiparallel b-sheet. The second
antiparallel b-sheet is formed between the residues Val116–
Pro117 (B3) and Gly131–Leu138 (B4). The remaining two b-
strands are formed between residues Thr142–Trp143 (B5) and
Asp155–Asp156 (B6). The b-strands of B3 and B4 are separated
by a long well deﬁned loop region, Cys118–Gly131.3.3. Docking interactions between GLP-2 and Nt-ECD
The docking interactions between the Nt-ECD and the GLP-2
hormone were performed using the HADDOCK web server. The
docking complex shown in Fig. 5a reveals that the N-terminal por-
tion of the hormone from His1 up to Asn16 makes no contacts with
the extracellular domain. The binding interface of the GLP-2 hor-
mone spans between the residues Leu17 and Lys30 indicating
the presence of a distinct pattern of intermolecular interactions.
The docking complex shows the intermolecular hydrogen bonding
interactions between the residues Asp21 and Lys30 of the GLP-2
hormone with the residues Thr72, Asp101, and Asp151 of the Nt-
ECD, respectively. The GLP-2 hormone has partly amphipathic
properties that allow the hydrophobic and hydrophilic interactions
of the hormone with the Nt-ECD (Fig. 5b). The hormone exposes
the hydrophobic residues Leu17, Ala18, Ala19, Phe22, Ile23,
Trp25, Ile27 and Thr29 towards the hydrophobic binding cavity
of the extracellular domain, favouring the hydrophobic interac-
tions between the GLP-2 and Nt-ECD. The hydrophobic binding
cavity of Nt-ECD is formed by the residues of three receptor seg-
ments: Leu69, Thr72 and Trp76 in the a-helix; Tyr103 and
Trp106 at the ends of the B2 strand; Pro119, Tyr121, Leu122,
Pro123, Trp124 and Trp125 in the loop region between the B3
and B4 strands. The hydrophilic interaction that promotes the
binding of the GLP-2 with the Nt-ECD occurs between the Lys30
of GLP-2 and the Asp101 and Asp151 residues of the receptor indi-
cating the important hormone–receptor recognition.
4. Discussion
The pharmacological importance of GLP-2 in the treatment of
intestinal injury has made the structural and biological studies of
GLP-2 and its analogues a subject of intense interest [10,22,23].
Fig. 5. Molecular docking interactions between the Nt-ECD and the GLP-2 hormone showing (a) intermolecular hydrogen bonding and (b) hydrophobic interactions in the
binding cavity. The YASARA software is used for presenting the ﬁgure.
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structural properties of the GLP-2 hormone or its receptor. To ad-
dress the importance of the structure function relationship of this
hormone and its receptor, we have decided to determine the solu-
tion structure of the GLP-2 hormone and its interaction with the
extracellular N-terminal receptor domain.
The NMR data obtained in 33% TFE–water mixed solvent system
showed complete TOCSY and NOESY correlations of amino acids
indicating the presence of folded structural features. The presence
of short range aiH/Ni+1H and NiH/Ni+1H intra-residue connectivi-
ties and clear medium range aiH/Ni+3H, aiH/bi+3H and aiH/Ni+4H
connectivities indicated the existence of the secondary structural
feature for the GLP-2 between the residues Phe6 and Ile27. The
C-terminal region beyond Ile27 showed some aiH/Ni+3H and aiH/
Ni+4H connectivities indicating a loose helical segment towardsthe end of the peptide while the N-terminal region up to Ser5
showed no clear structural features. A similar structure was also
proposed for the sister hormone GLP-1 and glucose-dependent
insulinotropic polypeptide (GIP) in TFE–water mixed solvent sys-
tem where helix formation is less well deﬁned in terminal regions
[24,25].
To understand the structural properties of the GLP-2 in mem-
brane mimicking media, we have used zwitterionic DHPC micelles
for further studies. The presence of aiH/Ni+1H, NiH/Ni+1H and aiH/
Ni+3H connectivities in the NOESY spectrum, revealed the occur-
rence of an a-helical secondary structure between the residues
Phe6 and Arg24 for GLP-2 in micellular medium. The presence of
weak aiH/Ni+3H and aiH/Ni+4H medium range connectivities be-
tween residues, Asn24 and Gln28, indicates a less well deﬁned
helical conformation in the C-terminal region of the peptide. The
Table 1
Structural statistics of GLP-2 in TFE–water and DHPC micellular media.
TFE–water DHPC micelles
NOE constraints used for calculations 430 365
NOE violations > 0.2 Å 8 10
Ramachandran plot regions (%)
Most favoured 82.7 60.7
Additional allowed 17.0 34.3
Generously allowed 0.0 4.7
Mean atomic RMSD (Å)
Backbone atoms 0.44 ± 0.14 (6–27) 0.94 ± 0.38 (6–24)
1.13 ± 0.37 (6–27)
Heavy atoms 1.42 ± 0.33 (6–27) 1.91 ± 0.59 (6–24)
2.04 ± 0.55 (6–27)
Average energies (kcal mol1)
Bond stretching 13.582 14.027
Angle bending 79.847 80.404
Torsional 79.962 80.279
Out of plane bending 0.487 0.604
1–4 Van der Waals 40.386 41.662
Van der Waals 149.890 142.749
Total 64.373 74.227
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plays a slight curvature, suggesting that the helix may assume a
phase shift with the hydrophobic residues concentrating towards
the membrane. This type of curvature is commonly found on a
variety of polypeptides in phospholipids media that indicates the
characteristic mobility and exchange properties of a surface-bound
peptide [26,27]. The calculated solution structures were analyzed
using the MOLMOL and the PROCHECK-NMR indicated that more
than 94% of the residues lie within allowed regions of the Rama-
chandran plot for both media (Table 1).
The structure of GLP-2 in DHPC micelles is similar to the other
peptide hormones such as, glucagon, secretin, vasoactive intestinal
peptide, exendin-4, GIP and GLP-1 in the same family. Glucagon
bound to dodecylphosphocholine micelles was found to adopt no
secondary structure between the residues 1 and 10 and an a-heli-
cal conformation between the residues 10 and 29 [28]. Similarly,
secretin underwent conformational change from random coil to
a-helix in the presence of distearoyl phosphatidylcholine polyeth-
ylene glycol [29]. Structural studies carried out for GIP in our lab-
oratory have shown a well deﬁned a-helical conformation for the
peptide in water [30] and in helix promoting solvents [31]. Studies
on GLP-1 in micellular media revealed two helical segments be-
tween 7–14 and 18–30 [32]. This similarity of forming a-helical
conformations in micellular media, suggests that the helical sur-
faces of glucagon/secretin family peptides, including the GLP-2,
interact with the micelles in a similar manner in which the a-heli-
cal segment of the peptide recognizes its receptor.
The homology model of the Nt-ECD presented in this paper
exhibits a similar overall fold to that observed in the glucagon/
secretin receptor super family [22]. The Nt-ECD core domain
consists of N-terminal signalling peptide, single a-helix and two
central antiparallel b-sheets that are stabilized by the three disul-
phide bridges (Cys83/Cys105, Cys96/Cys137 and Cys118/Cys159)
and ﬁve conserved residues (Asp101, Trp106, Pro119, Arg135,
Gly141 and Trp143). The docking studies shown here between
the Nt-ECD with the GLP-2 hormone reveal that the hormone is
sandwiched between the a-helix and two b-sheets of the Nt-ECD.
The slight curvature found for the GLP-2 in the DHPC micellular
media could play an important role at the hydrophobic cavity of
the Nt-ECD that allows the hydrophobic residues of the helix for
binding to the receptor with a larger hydrophobic face.
Furthermore, alanine scan studies carried out on GLP-2 hor-
mone highlighted that the residues Leu17, Arg20, Phe22, Trp25,
Leu26 and Lys30 were vital and play a critical role in receptor rec-ognition [10]. For the ﬁrst time, our docking model revealed inter-
actions of most of those residues, and highlighted the structural
determinants on the Nt-ECD indicating that the complex is in good
agreement with the other complexes solved by using X-ray crystal-
lography [33–35]. Despite the overall similarity in ECD ligand bind-
ing, there may be subtle differences in the binding mode within the
transmembrane domain and receptor activation. Studies con-
ducted by Neumann and co-workers revealed that a helix-capping
motif at the N-terminal plays a key role in the activation of the
class B GPCRs [36]. Although our modelled complex showed no
interactions between the GLP-2 residues between Phe6 and
Met10 and the Nt-ECD, we have identiﬁed a clear helical segment
in this region that could act as an helix capping motif which inter-
acts with the transmembrane domain as described by others [36].
5. Conclusion
Results obtained from the NMR studies of GLP-2 in both solvent
systems show similarities with the structures of other peptides in
the same family. In the TFE–water mixed solvent system, GLP-2
adopts an a-helical conﬁrmation between the residues Phe6 and
Ile27, while in DHPC micelles a well-deﬁned a-helix is formed be-
tween the residues Phe6 and Asn24. The receptor–hormone com-
plex presented in the paper shows molecular details of the GLP-2
binding with the Nt-ECD, which follows the two-domain mecha-
nism of the class B GPCR receptor. The structural and advanced
modelling studies described in this article could be useful for
designing receptor selective agonists or antagonists which may
lead to the development of drugs for intestinal injury and short bo-
wel syndrome.
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